AstraZeneca has agreed to buy U.S. company Ardea Biosciences for $1.26 billion, giving it a new gout drug to bolster its weak pipeline in a deal that feeds a wave of M&A in the biotechnology sector.
Astra fuels biotech M&A with $1.3 billion Ardea buy
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.